Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Jan 07, 2026

BUY
$21.87 - $57.56 $2,864 - $7,540
131 New
131 $5.3 Million
Q4 2024

Jan 07, 2026

BUY
$26.75 - $35.28 $3,504 - $4,621
131 New
131 $3.64 Million

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $2.52B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Aventura Private Wealth, LLC Portfolio

Follow Aventura Private Wealth, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aventura Private Wealth, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aventura Private Wealth, LLC with notifications on news.